Hjem › Akut bifænotypisk leukæmi › Texas › Houston
Akut bifænotypisk leukæmi kliniske forsøg i Houston, TX
11 studier for Akut bifænotypisk leukæmi søger deltagere på steder i og omkring Houston (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.
Officiel studietekst (engelsk)
Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RekruttererFase 1
- University of Texas MD Anderson Cancer Center, Houston
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
RekruttererFase 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
RekruttererFase 2
- M D Anderson Cancer Center, Houston
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RekruttererFase 3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RekruttererFase 1/2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RekruttererFase 1/2
- University of Texas MD Anderson Cancer Center, Houston
Personalized NK Cell Therapy in CBT
RekruttererFase 2
- M D Anderson Cancer Center, Houston
A Study of Revumenib and Mezigdomide in People With Leukemia
RekruttererFase 1/2
- MD Anderson Cancer Center (Data Collection Only), Houston
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
RekruttererFase 1/2
- M D Anderson Cancer Center, Houston
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
RekruttererFase 2
- M D Anderson Cancer Center, Houston
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RekruttererFase 1
- Texas Children's Hospital/Baylor College of Medicine, Houston
Akut bifænotypisk leukæmi forsøg i andre byer
- Seattle, WA15 studier
- New York City, NY10 studier
- Atlanta, GA9 studier
- Durham, NC8 studier
- Memphis, TN7 studier
- Chicago, IL7 studier
- Charlotte, NC6 studier
- Aurora, CO6 studier
- Baldwin Park, CA6 studier
- Portland, OR6 studier
- Los Angeles, CA6 studier
- Philadelphia, PA6 studier
Andre studier i Houston
- Ikke-småcellet lungecancer145 studier
- Brystkræft126 studier
- Kræft (alle typer)121 studier
- Metastatisk cancer104 studier
- Colorektal kræft102 studier
- Ægstockræft89 studier
- Akut myeloid leukæmi85 studier
- Lungecancer78 studier
- Prostatakræft76 studier
- Livmoderslimhindekræft68 studier
- Bugspytkirtelkræft61 studier
- Melanom59 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.